Recombinant Human AS3MT Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human AS3MT Protein, CF Summary

• Details of Functionality: Bioassay data are not available.
• Source: E. coli-derived human AS3MT protein
  Ala2-Cys375, with a C-terminal 6-His tag
• Accession #: Q9HBK9-1
• N-terminal Sequence: Ala2 & Ala3
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 42 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 41 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in Tris and NaCl with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in water.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human AS3MT Protein, CF

• Arsenic (+3 Oxidation State) Methyltransferase
• Arsenic Methyltransferase
• arsenite methyltransferase
• AS3MT
• CYT19
• CYT19methyltransferase cyt19
• EC 2.1.1.137
• Methylarsonite Methyltransferase
• Methyltransferase Cyt19
• S-Adenosyl-L-Methionine:Arsenic(III) Methyltransfe
• S-adenosyl-L-methionine:arsenic(III) methyltransferase
• S-Adenosylmethionine:Arsenic (III) Methyltransfera
• S-adenosylmethionine:arsenic (III) methyltransferase

Background

Arsenite methyltransferase (AS3MT) is a cytosolic, 42 kDa enzyme that belongs to the methyltransferase superfamily and catalyzes the transfer of a methyl group from S-adenosyl-L-methionine to arsenite. Arsenic exposure in humans results in a broad range of acute and chronic life-long health risks including cancer, diabetes, cardiovascular and neurological diseases (1-4). Specifically, in all regions of the brain, arsenic exposure can cause a dose-dependent accumulation of arsenic compounds that interfere with glucose transporter function and cause a neurotoxic effect (5). In contrast, some arsenic forms and metabolites of arsenic are effective as therapeutic treatments for cancer (4, 6-8). In humans, AS3MT biomethylation paradoxically detoxifies arsenic and produces carcinogenic metabolites (4, 9-10). Several polymorphisms in the AS3MT gene have been shown to affect the protein's catalytic activity and result in potentially increased risk of arsenic-related disease (11). AS3MT is expressed primarily in liver although it is present in lower abundance in other tissues (12). Expression is also observed in plaque-resident cells where it contributes to atherosclerosis (13) and a truncated isoform of AS3MT is found to have increased expression in the brain where it is associated with schizophrenia (14, 15).

1. Abernathy, C.O. et al. (2003) J. Nutr. 133:1536S.
2. Tchounwou, P.B. et al. (2003) Toxicol. Pathol. 31:575.
3. States, J.C. et al. (2009) Toxicol. Sci. 107:312.
4. Khairul, I. et al. (2017) Oncotarget 8:23905.
5. Rodriguez, V.M. et al. (2005) Toxicol. Sci. 84:157.
6. Dilda, P.J. and P.J Hogg (2007) Cancer Treat. Rev. 33:542.
7. Lalleman-Breitenback, V. et al. (2012) Trends. Mol. Med. 18:36.
8. Lengfedler, E. et al. (2012) Leukemia. 26:433.
9. Ajees, A.A. et al. (2012) Biochemistry. 51:5476.
10. Dheeman, D.S. et al. (2014) Chem. Res. Toxicol. 27:1979.
11. Li, J. et al. (2017) Chem. Res. Toxicol. 30:1481.
12. Kobayashi, Y. et al. (2007) Environ. Toxicol. Pharmacol. 23:115.
13. Negro Silva, L.F. et al. (2017) Environ Health Perspect. 125:077001.
14. Li, M. et al. (2016) Nat. Med. 22:649.
15. Li, L. et al. (2016) Mol. Neuropsychiatry 2:213.

Bioinformatics

• Uniprot:
  • Q9HBK9-1()